Online inquiry

IVTScrip™ mRNA-Anti-VWF, aVWF81(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ2227MR)

This product GTTS-WQ2227MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets VWF gene. The antibody can be applied in Acute coronary syndrome (ACS), Thrombotic thrombocytopenia purpura (TTP) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_000552.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 7450
UniProt ID P04275
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-VWF, aVWF81(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ2227MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ9558MR IVTScrip™ mRNA-Anti-TNFRSF17, J6M0(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA J6M0
GTTS-WQ10293MR IVTScrip™ mRNA-Anti-PCSK9, LGT209(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA LGT209
GTTS-WQ3857MR IVTScrip™ mRNA-Anti-IL6R, BCD-089(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA BCD-089
GTTS-WQ15095MR IVTScrip™ mRNA-Anti-TNC, ST2146(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ST2146
GTTS-WQ14638MR IVTScrip™ mRNA-Anti-DLL3, SC0001-SCX(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA SC0001-SCX
GTTS-WQ3613MR IVTScrip™ mRNA-Anti-FGFR2, BAY 1179470(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA BAY 1179470
GTTS-WQ11158MR IVTScrip™ mRNA-Anti-IFNAR1, MDX-1333(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA MDX-1333
GTTS-WQ6774MR IVTScrip™ mRNA-Anti-TACSTD2, DS-1062(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA DS-1062
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW